Dermatitis News

Patients with persistently controlled atopic dermatitis continued to experience stable and low disease activity after receiving reduced dosages of dupilumab, according to a study published in Allergy.

By inhibiting IL-4 and IL-13 signaling, dupilumab enabled the restoration of lipid composition and barrier function in the skin of patients with moderate to severe atopic dermatitis, according to a study published in Allergy.

Arcutis Biotherapeutics has completed patient enrollment for its phase 3 trial of roflumilast cream for the treatment of atopic dermatitis, the company announced in a press release.

Photoaggravated atopic dermatitis, which affects people of varied ages and with different skin phototypes, has a significant impact on quality of life, according to a study.

inimally invasive tape strips capture immune-related and barrier-related markers of atopic dermatitis in lesional and non-lesional skin across pediatric age groups, according to a letter published in Allergy.

Tralokinumab led to early and clinically meaningful improvements in patient-reported outcomes for moderate to severe atopic dermatitis compared with placebo, according to a study published in Annals of Allergy, Asthma & Immunology.

Asthma or atopic dermatitis among parents may predict atopic dermatitis risk in their offspring, according to recent findings.

Progressive improvement in atopic dermatitis symptoms was found with continued tralokinumab plus topical corticosteroids, according to a study.

Patients with mild to moderate atopic dermatitis experienced slight and potentially unimportant improvements with dietary elimination, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Atopic dermatitis disease burden is affected by severity and time spent managing the disease, according to a study.